The reiteration of a Speculative Buy rating and maintenance of a $3 price target by Benchmark is likely to positively influence investor sentiment towards Hoth Therapeutics. This could lead to a short-term increase in stock price as investors may view the reaffirmation as a sign of confidence in the company's potential.